SCHEDULE: Invus Group Discloses Yarrow Bioscience Stake

Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of 7.2% of Yarrow Bioscience, Inc. common stock as of September 17, 2026.

Summary

• Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP, along with their affiliated entities and Raymond Debbane, have collectively reported beneficial ownership of Yarrow Bioscience, Inc. common stock.
• As of September 11, 2026, Invus Public Equities held 591,472 shares, and Avicenna Fund held 83,528 shares.
• The total beneficial ownership reported by the group is 675,000 shares, representing 7.2% of the outstanding common stock.
• This ownership percentage is based on 8,572,309 shares outstanding as of September 11, 2026, plus an additional 865,384 shares from an underwriter's option exercised by September 14, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• Significant investment by Invus Group and Raymond Debbane indicates confidence in Yarrow Bioscience's long-term prospects.
• The filing clearly outlines the beneficial ownership structure and the entities involved.

Negatives

• The filing does not provide any new operational or financial performance data for Yarrow Bioscience.
• The disclosure is a Schedule 13G, which is typically filed by passive investors, suggesting no immediate intent to influence control, but could precede future strategic moves.

Risks

• Potential for increased market activity or volatility in Yarrow Bioscience's stock due to the significant stake held by Invus Group.
• Future actions by Invus Group, while currently passive, could impact the company's strategic direction or shareholder base.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Yarrow Bioscience's future performance.

Management Comments

• Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology sector, often indicating strategic investment or accumulation by institutional investors or investment groups.

Stakeholder Impact

• Shareholders: May see increased interest in the stock, potentially leading to price fluctuations. The passive nature of the filing suggests no immediate change in control.
• Management of Yarrow Bioscience: Will be aware of the significant stake held by Invus Group, which could influence future strategic discussions or board composition if ownership increases.

Next Steps

• Monitoring of future filings by Invus Group and Raymond Debbane for any changes in beneficial ownership or strategic intent.
• Observation of Yarrow Bioscience's operational and financial performance to assess the impact of significant investor interest.

Key Dates

Keywords

Yarrow Bioscience, Invus Group, Raymond Debbane, Schedule 13G, Beneficial Ownership, Common Stock, Investment